Literature summary for 3.4.14.10 extracted from

Usukura, K.; Kasamatsu, A.; Okamoto, A.; Kouzu, Y.; Higo, M.; Koike, H.; Sakamoto, Y.; Ogawara, K.; Shiiba, M.; Tanzawa, H.; Uzawa, K.
Tripeptidyl peptidase II in human oral squamous cell carcinoma (2013), J. Cancer Res. Clin. Oncol., 139, 123-130.

Search for more literature for 3.4.14.10

Application

Application	Comment	Organism
medicine	TPP2 mRNA and protein are significantly up-regulated in oral squamous cell carcinoma-derived cells compared with human normal oral keratinocytes. Suppression of TPP2 expression with shRNA significantly inhibit cellular proliferation compared with the control cells. In addition, appropriate localization of cellular proliferation and spindle assembly checkpoint molecules MAD2 and upregulation of CCNB1 are observed in TPP2 knockdown oral squamous cell carcinoma cells. TPP2 expression in primary oral squamous cell carcinomas is significantly greater than that in the normal oral counterparts, and the TPP2-positive cases are significantly correlated with tumor size	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-
Homo sapiens	P29144	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
Ca9-22 cell	-	Homo sapiens	-
HO-1-N-1 cell	-	Homo sapiens	-
HSC-2 cell	-	Homo sapiens	-
HSC-3 cell	-	Homo sapiens	-
HSC-4 cell	-	Homo sapiens	-
oral squamous cell carcinoma cell	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
TPP II	-	Homo sapiens
tripeptidyl aminopeptidase I I	-	Homo sapiens

Expression

Organism	Comment	Expression
Homo sapiens	highly up-regulated in oral squamous cell carcinoma-derived cells	up
Homo sapiens	TPP2 mRNA and protein are significantly up-regulated in oral squamous cell carcinoma-derived cells compared with human normal oral keratinocytes	up

General Information

General Information	Comment	Organism
malfunction	suppression of TPP2 expression with shRNA significantly inhibits cellular proliferation compared with the control cells	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)